Capricor Therapeutics (CAPR) Net Equity Issued and Repurchased (2013 - 2025)

Capricor Therapeutics' Net Equity Issued and Repurchased history runs 12 years deep, the most recent figure standing at $77.5 million for Q4 2025.

• In Q4 2025, Net Equity Issued and Repurchased fell 4.13% year-over-year to $77.5 million; the TTM figure through Dec 2025 stood at $175.3 million (up 75.12% YoY), while the FY2025 annual figure was $237.0 million, up 55.61% from the prior year.
• Net Equity Issued and Repurchased for Q4 2025 stood at $77.5 million, down from $80.8 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $80.8 million in Q4 2024, with the low at $221081.0 in Q3 2023.
• The 5-year median for Net Equity Issued and Repurchased is $5.2 million (2021), against an average of $17.0 million.
• The sharpest annual moves came in 2021 and 2024: Net Equity Issued and Repurchased tumbled 96.53% in 2021, then surged 6684.84% in 2024.
• Capricor Therapeutics' Net Equity Issued and Repurchased stood at $7.5 million in 2021, then slumped by 61.02% to $2.9 million in 2022, then soared by 692.41% to $23.2 million in 2023, then jumped by 248.99% to $80.8 million in 2024, then fell by 4.13% to $77.5 million in 2025.
• Business Quant data shows CAPR's Net Equity Issued and Repurchased at $77.5 million in Q4 2025, $80.8 million in Q4 2024, and $15.0 million in Q3 2024.